SCHEMBL2425272

SCHEMBL2425272

[CH](Cc1ccccn1)N1CCNCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
TSHR P16473 2/20 0.51
SLC6A4 P31645 1/20 0.51
ALOX15 P16050 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PLD1 Q13393 1/20 0.49
CXCR4 P61073 2/20 0.42
HTR7 P34969 2/20 0.42
KDM4E B2RXH2 1/20 0.41
NMT1 P30419 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
CYP2C19 P33261 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 1/20 0.40
HTR1A P08908 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903097 0.76 ALDH1A1 (0.61) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL17485679 0.76 ALDH1A1 (0.61) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL209471 0.76 ALDH1A1 (0.61) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL3432550 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL3387061 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL23926185 0.75 ALDH1A1 (0.52) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
Hydrochloric Acid SCHEMBL27587923 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
SCHEMBL3383287 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
Hydrochloric Acid SCHEMBL30163937 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1
Piperazine SCHEMBL28106509 0.75 ALDH1A1 (0.60) ALDH1A1TSHRSLC6A4ALOX15L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US claimed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP claimed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP claimed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US claimed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO claimed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 ALDH1A1 323/4885TSHR 172/4885SLC6A4 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.